

Effect of Gliclazide or Gliclazide plus Metformin Combination on Glycemic Control in Patients with T2DM in India: A Real-World, Retrospective, Longitudinal, Observational Study from Electronic Medical Records

Polavarapu NK, et al. Drugs Real World Outcomes. 2020 Dec; 7(4):271-279.

- Patients were categorized into gliclazide only (n = 66), gliclazide + metformin (n = 179), gliclazide add-on (n = 169), and gliclazide + metformin add-on (n = 84) groups.
- Gliclazide 80 mg + metformin 500 mg twice daily was the most prescribed regimen in the gliclazide + metformin group (69.3%).
- Mean change in HbA1c among patients with baseline HbA1c >7% was -0.8% in gliclazide only group; **-1.6% in gliclazide + metformin group**; -1.2% in add-on gliclazide group; and -1.4% in add-on gliclazide + metformin group.

Gliclazide + Metformin twice daily therapy is the most effective in reducing HbA1c (>1.6%) in diabetic patients, thus validating their role in glycemic control in patients with T2DM in India.